KRAS G12C

Clinical trials for KRAS G12C explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C trials appear

Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 7 Not yet recruiting 1 Not yet finished but already full! 2 Completed 1

New drug targets 'Undruggable' cancer mutation in major trial

Disease control Completed

This clinical trial tested a new oral drug called GFH925 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study aimed to find a safe dose and see if the drug could shrink tumors in cancers like non-small cell lung cancer and colorect…

Matched conditions: KRAS G12C

Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control

Last updated Apr 01, 2026 22:56 UTC

KRAS G12C

Get alerted when new KRAS G12C trials appear

New drug targets 'Undruggable' cancer mutation in major trial